Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: A population-based examination

Journal of Gastrointestinal Surgery

Volumn 11, Issue 1, 2007, Pages 114-125

  Perez, Eduardo A ^a   Gutierrez, Juan C ^a   Jin, Xiaoling ^a   Lee, David J ^a   Rocha Lima, Caio ^a   Livingstone, Alan S ^a   Franceschi, Dido ^a   Koniaris, Leonidas G ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Epidemiology; Sarcoma; SEER; STI 571

Indexed keywords

ARTICLE; CANCER REGISTRY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; HEALTH SURVEY; HUMAN; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REGISTER; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MULTIVARIATE ANALYSIS; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; SARCOMA; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 34250174793     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-006-0072-0     Document Type: Conference Paper

References (26)

1. Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3(11):655-664.
2. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br J Surg 2003;90(10):1178-1186.
3. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005;103(4):821-829.
4. Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including GIST. J Am Coll Surg 2006;202(4):623-629, Apr.
5. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29(1):52-68.
6. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152(5):1259-1269.
7. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol 2002;33(5):459-465.
8. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279(5350):577-580.
9. Hirota S, Isozaki K, Nishida T, Kitamura Y. Effects of loss-of-ftmction and gain-of-function mutations of c-kit on the gastrointestinal tract. J Gastroenterol 2000;35(Suppl 12):75-79.
10. Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene, Gastroenterology 2002;122(5):1493-1499.
11. Li FP, Fletcher JA, Heinrich MC, et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 2005;23(12):2735-2743.
12. Fletcher JA, Fleteher CD, Rubin BP, et al. KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized? Am J Pathol 2002;161(2):737-738, author reply 738-739.
13. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28(7):889-894.
14. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-480.
15. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8(10):3034-3038.
16. Clary BM, DeMatteo RP, Lewis JJ, et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2002;8(4):290-299.
17. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International Classification of Diseases for Oncology. Third Edition. Geneva: World Heath Organization, 2000.
18. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231(1):51-58.
19. Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992;69(6):1334-1341.
20. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000, Am J Gastroenterol 2005;100(1):162-168.
21. Plaat BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18(18):3211-3220.
22. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase 1 study. Lancet 2001;358(9291):1421-1423.
23. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364(9440):1127-1134.
24. Wu PC, Langerman A, Ryan CW, et al. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 2003;134(4):656-665, discussion 665-666.
25. Cunningham SC, Kamangar F, Kim MP, et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg 2005;9(5):718-725.
26. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003;238(3):358-370, discussion 370-371.